Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus

Fabrizio Stocchi*, Angelo Antonini, Daniela Berg, Bruno Bergmans, Wolfgang Jost, Regina Katzenschlager, Jaime Kulisevsky, Per Odin, Francesc Valldeoriola, K. Ray Chaudhuri

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Safinamide is a highly selective, reversible MAO B-inhibitor recently marketed in European and North American countries. To better define clinical indications regarding motor and non-motor symptoms, targeted population and safety of this compound, ten movement disorders specialists, experts in their field, convened and developed a panel of statements on: the role of glutamate in Parkinson’s disease, introduction to fluctuations, efficacy of safinamide on motor symptoms, motor complications and non-motor symptoms, quality of life, safety of safinamide and target population for use. Strong consensus was reached for all the statements on the efficacy of safinamide on motor symptoms, motor fluctuations, quality of life and safety. Among non-motor symptoms, a positive consensus was reached for the symptoms sleep/fatigue, mood, and pain while there was a lack of consensus for the statements regarding the efficacy of safinamide in improving cognition, urinary and sexual functions. The statement on orthostatic hypotension obtained a negative consensus. The consistent and large agreement reached in this Delphi panel perfectly reflects the perception of efficacy, safety and tolerability of safinamide as evident from pivotal trials and clinical practice and shows how these findings may guide movement disorders specialists in their clinical therapeutic approach. The impact of non-motor symptoms in PD is considerable, and management remains an unmet need. In this context, the ability of safinamide to impact some non-motor symptoms may represent the most promising and distinctive feature of this compound and deserves further investigations.

Original languageEnglish
Article number17
Journalnpj Parkinson's Disease
Volume8
Issue number1
DOIs
Publication statusPublished - 21 Feb 2022

Fingerprint

Dive into the research topics of 'Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus'. Together they form a unique fingerprint.

Cite this